---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-114422"
form_type: "8-K"
ticker: "ABT"
cik: "0000001800"
company_name: "ABBOTT LABORATORIES"
filed_at: "2025-11-20T23:59:59+00:00"
generated_at: "2026-05-16T18:08:50.525767+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Abbott to acquire Exact Sciences for $105/share, total equity value ~$21B

## Summary
- Abbot buys Exact Sciences for $105 per share in cash; equity value ~$21B, enterprise value ~$23B.
- Exact Sciences 2025 revenue >$3B with high-teens organic growth; adds cancer diagnostics vertical.
- Close expected Q2 2026, subject to Exact Sciences shareholder vote and regulatory approvals (incl. HSR).
- Immediately accretive to Abbott's revenue growth (+50bps Abbott, +300bps Diagnostics) and gross margin (+100bps).
- Financing via cash and up to $20B bridge loan from Morgan Stanley; initial 2026 debt/EBITDA ~2.7x.

## SEC filing metadata
- accession: 0001104659-25-114422
- form_type: 8-K
- ticker: ABT
- cik: 0000001800
- company_name: ABBOTT LABORATORIES
- filed_at: 2025-11-20T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800/000110465925114422/0001104659-25-114422-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800/000110465925114422/tm2531676d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-114422
- JSON: https://secwatch.observer/filing/0001104659-25-114422.json
- Plain text: https://secwatch.observer/filing/0001104659-25-114422.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.